Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation

M. S. Leffell, K. Cao, M. Coppage, J. A. Hansen, J. M. Hart, N. Pereira, S. Pereira, N. L. Reinsmoen, D. Senitzer, A. Smith, M. Torres, R. Vega, Ephraim J Fuchs

Research output: Contribution to journalArticle

Abstract

As part of the 15th International Histocompatibility and Immunogenetics Workshop (IHIWS), seven centers participated in a collaborative project to determine whether any significant humoral sensitization occurred post-transplant among recipients of HLA partially mismatched hematopoietic cell transplants (HCTs). A total of 140 donor/recipient pairs were enrolled with a total of 367 pre-and post-transplant sera analyzed. The majority of the samples (69.1%) were obtained within 30-90 days post-HCT. HLA-specific antibodies were defined using single antigen bead assays on a LuminexTM platform with a positive cutoff value of 1000 normalized median fluorescence intensity (MFI). There was an overall incidence of post-HCT sensitization toward donor HLA mismatches of 5.7%; however, all cases were among recipients of one HLA haplotype-mismatched grafts under nonmyeloablative, pre-transplant conditioning. Among the one haplotype-mismatched recipients, 15.7% (8/51) developed donor HLA-specific antibodies and 29.4% also had antibodies directed toward third party HLA antigens. Among the donor-specific antibodies, 9.8% were directed toward HLA class I antigens; 7.8% were against class II antigens; and 2.0% had both class I and II specificity. The relative strength of post-transplant antibodies was low with no significant difference in the mean maximum MFI values between third party and donor-specific antibodies. Because only a small number (10.2%) of the post-transplant samples were obtained 180 days or more post-HCT, longer term study is needed to evaluate any clinical relevance of these low-to-moderate levels of donor-specific antibody in one haplotype-mismatched recipients, as well as to determine whether any other antibodies occur at later times.

Original languageEnglish (US)
Pages (from-to)494-498
Number of pages5
JournalTissue Antigens
Volume74
Issue number6
DOIs
StatePublished - Dec 2009

Fingerprint

Hematopoietic Stem Cell Transplantation
Transplants
Incidence
Antibodies
Tissue Donors
Haplotypes
HLA Antigens
Fluorescence
Immunogenetics
Histocompatibility Antigens Class I
Histocompatibility
Histocompatibility Antigens Class II
Education
Antigens

Keywords

  • Alloantibodies
  • Hematopoietic cell transplants
  • Human leukocyte antigen mismatched transplants
  • Human leukocyte antigen specific antibodies
  • Nonmyeloablative hematopoietic cell transplants

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Genetics

Cite this

Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation. / Leffell, M. S.; Cao, K.; Coppage, M.; Hansen, J. A.; Hart, J. M.; Pereira, N.; Pereira, S.; Reinsmoen, N. L.; Senitzer, D.; Smith, A.; Torres, M.; Vega, R.; Fuchs, Ephraim J.

In: Tissue Antigens, Vol. 74, No. 6, 12.2009, p. 494-498.

Research output: Contribution to journalArticle

Leffell, MS, Cao, K, Coppage, M, Hansen, JA, Hart, JM, Pereira, N, Pereira, S, Reinsmoen, NL, Senitzer, D, Smith, A, Torres, M, Vega, R & Fuchs, EJ 2009, 'Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation', Tissue Antigens, vol. 74, no. 6, pp. 494-498. https://doi.org/10.1111/j.1399-0039.2009.01377.x
Leffell, M. S. ; Cao, K. ; Coppage, M. ; Hansen, J. A. ; Hart, J. M. ; Pereira, N. ; Pereira, S. ; Reinsmoen, N. L. ; Senitzer, D. ; Smith, A. ; Torres, M. ; Vega, R. ; Fuchs, Ephraim J. / Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation. In: Tissue Antigens. 2009 ; Vol. 74, No. 6. pp. 494-498.
@article{61e78a497d854c9c829d0f9794f03398,
title = "Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation",
abstract = "As part of the 15th International Histocompatibility and Immunogenetics Workshop (IHIWS), seven centers participated in a collaborative project to determine whether any significant humoral sensitization occurred post-transplant among recipients of HLA partially mismatched hematopoietic cell transplants (HCTs). A total of 140 donor/recipient pairs were enrolled with a total of 367 pre-and post-transplant sera analyzed. The majority of the samples (69.1{\%}) were obtained within 30-90 days post-HCT. HLA-specific antibodies were defined using single antigen bead assays on a LuminexTM platform with a positive cutoff value of 1000 normalized median fluorescence intensity (MFI). There was an overall incidence of post-HCT sensitization toward donor HLA mismatches of 5.7{\%}; however, all cases were among recipients of one HLA haplotype-mismatched grafts under nonmyeloablative, pre-transplant conditioning. Among the one haplotype-mismatched recipients, 15.7{\%} (8/51) developed donor HLA-specific antibodies and 29.4{\%} also had antibodies directed toward third party HLA antigens. Among the donor-specific antibodies, 9.8{\%} were directed toward HLA class I antigens; 7.8{\%} were against class II antigens; and 2.0{\%} had both class I and II specificity. The relative strength of post-transplant antibodies was low with no significant difference in the mean maximum MFI values between third party and donor-specific antibodies. Because only a small number (10.2{\%}) of the post-transplant samples were obtained 180 days or more post-HCT, longer term study is needed to evaluate any clinical relevance of these low-to-moderate levels of donor-specific antibody in one haplotype-mismatched recipients, as well as to determine whether any other antibodies occur at later times.",
keywords = "Alloantibodies, Hematopoietic cell transplants, Human leukocyte antigen mismatched transplants, Human leukocyte antigen specific antibodies, Nonmyeloablative hematopoietic cell transplants",
author = "Leffell, {M. S.} and K. Cao and M. Coppage and Hansen, {J. A.} and Hart, {J. M.} and N. Pereira and S. Pereira and Reinsmoen, {N. L.} and D. Senitzer and A. Smith and M. Torres and R. Vega and Fuchs, {Ephraim J}",
year = "2009",
month = "12",
doi = "10.1111/j.1399-0039.2009.01377.x",
language = "English (US)",
volume = "74",
pages = "494--498",
journal = "HLA",
issn = "2059-2302",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation

AU - Leffell, M. S.

AU - Cao, K.

AU - Coppage, M.

AU - Hansen, J. A.

AU - Hart, J. M.

AU - Pereira, N.

AU - Pereira, S.

AU - Reinsmoen, N. L.

AU - Senitzer, D.

AU - Smith, A.

AU - Torres, M.

AU - Vega, R.

AU - Fuchs, Ephraim J

PY - 2009/12

Y1 - 2009/12

N2 - As part of the 15th International Histocompatibility and Immunogenetics Workshop (IHIWS), seven centers participated in a collaborative project to determine whether any significant humoral sensitization occurred post-transplant among recipients of HLA partially mismatched hematopoietic cell transplants (HCTs). A total of 140 donor/recipient pairs were enrolled with a total of 367 pre-and post-transplant sera analyzed. The majority of the samples (69.1%) were obtained within 30-90 days post-HCT. HLA-specific antibodies were defined using single antigen bead assays on a LuminexTM platform with a positive cutoff value of 1000 normalized median fluorescence intensity (MFI). There was an overall incidence of post-HCT sensitization toward donor HLA mismatches of 5.7%; however, all cases were among recipients of one HLA haplotype-mismatched grafts under nonmyeloablative, pre-transplant conditioning. Among the one haplotype-mismatched recipients, 15.7% (8/51) developed donor HLA-specific antibodies and 29.4% also had antibodies directed toward third party HLA antigens. Among the donor-specific antibodies, 9.8% were directed toward HLA class I antigens; 7.8% were against class II antigens; and 2.0% had both class I and II specificity. The relative strength of post-transplant antibodies was low with no significant difference in the mean maximum MFI values between third party and donor-specific antibodies. Because only a small number (10.2%) of the post-transplant samples were obtained 180 days or more post-HCT, longer term study is needed to evaluate any clinical relevance of these low-to-moderate levels of donor-specific antibody in one haplotype-mismatched recipients, as well as to determine whether any other antibodies occur at later times.

AB - As part of the 15th International Histocompatibility and Immunogenetics Workshop (IHIWS), seven centers participated in a collaborative project to determine whether any significant humoral sensitization occurred post-transplant among recipients of HLA partially mismatched hematopoietic cell transplants (HCTs). A total of 140 donor/recipient pairs were enrolled with a total of 367 pre-and post-transplant sera analyzed. The majority of the samples (69.1%) were obtained within 30-90 days post-HCT. HLA-specific antibodies were defined using single antigen bead assays on a LuminexTM platform with a positive cutoff value of 1000 normalized median fluorescence intensity (MFI). There was an overall incidence of post-HCT sensitization toward donor HLA mismatches of 5.7%; however, all cases were among recipients of one HLA haplotype-mismatched grafts under nonmyeloablative, pre-transplant conditioning. Among the one haplotype-mismatched recipients, 15.7% (8/51) developed donor HLA-specific antibodies and 29.4% also had antibodies directed toward third party HLA antigens. Among the donor-specific antibodies, 9.8% were directed toward HLA class I antigens; 7.8% were against class II antigens; and 2.0% had both class I and II specificity. The relative strength of post-transplant antibodies was low with no significant difference in the mean maximum MFI values between third party and donor-specific antibodies. Because only a small number (10.2%) of the post-transplant samples were obtained 180 days or more post-HCT, longer term study is needed to evaluate any clinical relevance of these low-to-moderate levels of donor-specific antibody in one haplotype-mismatched recipients, as well as to determine whether any other antibodies occur at later times.

KW - Alloantibodies

KW - Hematopoietic cell transplants

KW - Human leukocyte antigen mismatched transplants

KW - Human leukocyte antigen specific antibodies

KW - Nonmyeloablative hematopoietic cell transplants

UR - http://www.scopus.com/inward/record.url?scp=70449331681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449331681&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0039.2009.01377.x

DO - 10.1111/j.1399-0039.2009.01377.x

M3 - Article

C2 - 19804563

AN - SCOPUS:70449331681

VL - 74

SP - 494

EP - 498

JO - HLA

JF - HLA

SN - 2059-2302

IS - 6

ER -